- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
The Endocrine Society
Empagliflozin Use Could Reduce Risk of Kidney Stones in T2D
June 16, 2022
An analysis of 20 randomized clinical trials comparing empagliflozin against placebo therapy in patients with type 2 diabetes suggests use of the SGLT2 inhibitor could reduce risk of developing kidney stones by nearly 40%.
Fezolinetant Reduces Menopause Symptoms, Could Improve Sleep
June 15, 2022
New data from the SKYLIGHT 2 trial demonstrate the reductions in frequency and severity of vasomotor menopausal symptoms in midlife women associated with the use of fezolinetant as well as potential improvements in sleep associated with use of the neurokinin-3 receptor antagonist from Astellas Pharma.
In Pediatric T1D, Race, Income, & Insurance Type Remain Significant Barriers to Insulin Pump Use
June 14, 2022
An analysis of the SEARCH for Youth in Diabetes presented at ENDO 2022 details historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.
Endocrine Society Releases New Guidelines for Managing Hyperglycemia in Noncritical Settings
June 14, 2022
On June 12, the Endocrine Society released new guidance for management of hyperglycemia in adult patients in noncritical care settings, which are cosponsored by the AACE, ADA, ADCES, and ESE.
Prediabetes Linked to Increased Risk of Myocardial Infarction
June 13, 2022
An analysis of the National Inpatient Sample at ENDO 2022 provides insight into the risk of myocardial infarction associated with prediabetes compared against normoglycemic patients.
Teprotumumab Linked to Hearing Loss, Tinnitus in New Study
March 26, 2021
A single-center study presented at ENDO 2021 suggests more than half of the patients with thyroid eye disease patients treated with teprotumumab (Tepezza) developed otologic symptoms.
Expanded Doses of Dulaglutide Safe, Efficacious Regardless of Baseline HbA1c
March 25, 2021
Juan Frias, MD, breaks down results of a post-hoc analysis of the AWARD-11 study examining expanded doses of dulaglutide according to baseline HbA1c levels.
Study Calls for Increased Screening of Primary Aldosteronism
March 25, 2021
An analysis presented at ENDO 2021 suggests less than 5% of patients at high risk for primary aldosteronism undergo screening and most screenings occur after the onset of symptoms.
COVID-19 Could Cause Atypical Thyroid Inflammation
March 24, 2021
A study from ENDO 2021 indicates moderate-to-severe COVID-19 infections are associated with atypical thyroid inflammation.
Alternating Doses of Denosumab Therapy Equally as Effective, Real-World Study Finds
March 24, 2021
Switching from 60 mg to 30 mg denosumab every 6 months could be an option for patients who have completed long-term denosumab therapy, according to the results of a new study from McMaster University.